MWMargot Wenzel

Margot Wenzel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margot Wenzel has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Angela Casini

    Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich, Lichtenbergstr. 4, D-85748 Garching b. München, Germany

    7 shared publications
  • Pierre Le Gendre

    Université Bourgogne Europe, CNRS, ICMUB UMR 6302

    4 shared publications
  • Philippe Richard

    Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France

    3 shared publications
  • Benoît Bertrand

    Institut Parisien de Chimie Moléculaire (IPCM), Sorbonne Université , CNRS, 4 Place Jussieu

    2 shared publications
  • Emilia Bigaeva

    Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen , Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

    2 shared publications
  • Ewen Bodio

    Institut de Chimie Moléculaire de l’Université de Bourgogne, Université de Bourgogne, CNRS UMR 6302, Dijon 21078, France

    2 shared publications

Latest Publications

  • Synthèse de complexes organobimétalliques à activité biologique

    by Margot Wenzel

    Un axe de recherche particulièrement développé en chimie organométallique moderneconcerne la recherche d’agents chimiothérapeutiques alternatifs au cisplatine dans lestraitements contre le cancer. Dans ce domaine, plusieurs stratégies ont été développées depuisplusieurs dizaines d’années, parmi lesquelles nous pouvons citer la multinucléarité, consistanten la création d’édifices polymétalliques. L’objectif de la première partie de ce manuscrits’inscrit dans cette thématique, par la conception, l’obtention et l’étude des propriétésbiologiques de complexes hétérobimétalliques "early-late" (Ti-Ru, Ti-Au, Ti-Pt, Ti-Os, Ti-Rh, Ti-Ir) et "late-late" (Pt-Au). Un deuxième concept développé au cours de ce manuscritconsiste en la génération de nouvelles espèces théranostiques, par association au sein d’unmême complexe d’un fragment métallique à activité thérapeutique et d’une sonde fluorescentepermettant de visualiser le trajet et les cibles biologiques de ce premier. Dans ce cadre, deuxséries parallèles de complexes bimétalliques ont été synthétisées à partir des squelettesRu(bipy)32+ et Ru(bipy)2(dipy)2+ dont les propriétés de luminescence ont été largementdécrites et utilisées pour diverses applications. Ces composés bimétalliques ont pu fairel’objet de mesures sur les deux fronts, à savoir leur activité cytotoxique envers des lignéescellulaires cancéreuses et leurs propriétés photophysiques.

  • Open Access

    Cyclometalated AuIII Complexes for Cysteine Arylation in Zinc Finger Protein Domains: towards Controlled Reductive Elimination

    by Margot N. Wenzel, Riccardo Bonsignore, Sophie R. Thomas, Didier Bourissou, Giampaolo Barone, Angela Casini

    With the aim of exploiting the use of organometallic species for the efficient modification of proteins through C‐atom transfer, the gold‐mediated cysteine arylation through a reductive elimination process occurring from the reaction of cyclometalated AuIII C^N complexes with a zinc finger peptide (Cys2His2 type) is here reported. Among the four selected AuIII cyclometalated compounds, the [Au(CCON)Cl2] complex featuring the 2‐benzoylpyridine (CCON) scaffold was identified as the most prone to reductive elimination and Cys arylation in buffered aqueous solution (pH 7.4) at 37 °C by high‐resolution LC electrospray ionization mass spectrometry. DFT and quantum mechanics/molecular mechanics (QM/MM) studies permitted to propose a mechanism for the title reaction that is in line with the experimental results. Overall, the results provide new insights into the reactivity of cytotoxic organogold compounds with biologically important zinc finger domains and identify initial structure–activity relationships to enable AuIII‐catalyzed reductive elimination in aqueous media.


  • Selective targeting of PARP-1 zinc finger recognition domains with Au( iii ) organometallics

    by Margot N. Wenzel, Samuel M. Meier-Menches, Thomas L. Williams, Eberard Rämisch, Giampaolo Barone, Angela Casini

    Insights into gold finger formation by organometallics and implications for targeting pharmacologically relevant zinc-finger proteins.


  • Redox Couple Involving NOx in Aerobic Pd-Catalyzed Oxidation of sp3-C–H Bonds: Direct Evidence for Pd–NO3–/NO2– Interactions Involved in Oxidation and Reductive Elimination

    by Margot N. Wenzel, Philippa K. Owens, Joshua T. W. Bray, Jason M. Lynam, Pedro M. Aguiar, Christopher Reed, James D. Lee, Jacqueline F. Hamilton, Adrian C. Whitwood, Ian J. S. Fairlamb

    NaNO3 is used in oxidative Pd-catalyzed processes as a complementary co-catalyst to common oxidants, e.g., CuII salts, in C–H bond activation and Wacker oxidation processes. NaNO3 and NaNO2 (with air or O2) assist the sp3-C–H bond acetoxylation of substrates bearing an N-directing group. It has been proposed previously that a redox couple is operative. The role played by NOx anions is examined in this investigation. Evidence for an NOx anion interaction at PdII is presented. Palladacyclic complexes containing NOx anions are competent catalysts for acetoxylation of 8-methylquinoline, with and without exogenous NaNO3. The oxidation of 8-methylquinoline to the corresponding carboxylic acid has also been noted at PdII. 18O-Labeling studies indicate that oxygen derived from nitrate appears in the acetoxylation product, the transfer of which can only occur by interaction of 18O at Pd with a coordinating-acetate ligand. Nitrated organic intermediates are formed under catalytic conditions, which are converted to acetoxylation products, a process that occurs with (50 °C) and without Pd (110 °C). A catalytically competent palladacyclic dimer intermediate has been identified. Head-space analysis measurements show that NO and NO2 gases are formed within minutes on heating catalytic mixtures to 110 °C from room temperature. Measurements by in situ infrared spectroscopy show that N2O is formed in sp3-C–H acetoxylation reactions at 80 °C. Studies confirm that cyclopalladated NO2 complexes are rapidly oxidized to the corresponding NO3 adducts on exposure to NO2(g). The investigation shows that NOx anions act as participating ligands at PdII in aerobic sp3-C–H bond acetoxylation processes and are involved in redox processes.


  • Bifunctional Chalcogen Linkers for the Stepwise Generation of Multimetallic Assemblies and Functionalized Nanoparticles

    by Jonathan A. Robson, Ferran Gonzàlez de Rivera, Khairil A. Jantan, Margot N. Wenzel, Andrew J. P. White, Oriol Rossell, James D. E. T. Wilton-Ely

    The disulfide ligand (SC6H4CO2H-4)2 acts as a simple but versatile linker for a range of group 8 transition metals through reaction of the oxygen donors. This leads to a range of homobimetallic ruthenium and osmium alkenyl compounds, [{M(CH═CHR)(CO)(PPh3)2(O2CC6H4S-4)}2] (M = Ru, Os; R = C6H4Me-4). Additional metal-based functionality can be added through the use of precursors incorporating rhenium bipyridine units (R = (bpy)ReCl(CO)3). The more robust diphosphine ligands in [{Ru(dppm)2(O2CC6H4S-4)}2]2+ (dppm = diphenylphosphinomethane) allow reduction of the disulfide bond with sodium borohydride to yield the thiol complex [Ru(O2CC6H4SH-4)(dppm)2]+. This complex reacts with [AuCl(PPh3)] to afford the bimetallic compound [Ru(dppm)2(O2CC6H4S-4)Au(PPh3)]+. However, an improved route to the same and related heterobimetallic compounds is provided by the reaction of cis-[RuCl2(dppm)2] with [Au(SC6H4CO2H-4)(L)] (L = PPh3, PCy3, PMe3, IDip) in the presence of base and NH4PF6 (IDip = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene). The heterotrimetallic compound [Au(SC6H4CO2Ru(dppm)2)2]+ is accessible through the reaction of the homoleptic gold(I) dithiolate [Au(SC6H4CO2H-4)2]PPN (PPN = bis(triphenylphosphine)iminium) with cis-[RuCl2(dppm)2]. Without departure from the same methodology, greater complexity can be incorporated into the system to provide the penta- and heptametallic assemblies [(dppf){AuSC6H4CO2Ru(dppm)2}2]2+ and [(dppf){AuSC6H4CO2Os(CH═CH-bpyReCl(CO)3)(CO)(PPh3)2}2]. The same stepwise approach provides the dinuclear organometallic complexes [(L)Au(SC6H4CO2-4)M(CH═CHC6H4Me-4)(CO)(PPh3)2] (M = Ru, Os; L = PPh3, IDip). Complexes containing three metals from different groups of the periodic table [(L)Au(SC6H4CO2-4)M{CH═CH-bpyReCl(CO)3}(CO)(PPh3)2] (M = Ru, Os) can also be prepared, with one ruthenium example (L = PPh3) being structurally characterized. In order to illustrate the versatility of this approach, the synthesis and characterization (IR and NMR spectroscopy, TEM, EDS, and TGA) of the functionalized gold and palladium nanoparticles Au@[SC6H4CO2Ru(dppm)2]+ and Pd@[SC6H4CO2Ru(dppm)2]+ is reported.


  • Toward anticancer gold-based compounds targeting PARP-1: a new case study

    by A. Citta, V. Scalcon, P. Göbel, B. Bertrand, M. Wenzel, A. Folda, M. P. Rigobello, E. Meggers, A. Casini

    A new gold(III) complex bearing a 2-((2,2′-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.


  • New Luminescent Polynuclear Metal Complexes with Anticancer Properties: Toward Structure–Activity Relationships

    by Margot Wenzel, Andreia de Almeida, Emilia Bigaeva, Paul Kavanagh, Michel Picquet, Pierre Le Gendre, Ewen Bodio, Angela Casini

    A series of new heterodinuclear luminescent complexes with two different organic ligands have been synthesized and characterized. A luminescent RuII(polypyridine) moiety and a metal-based anticancer fragment (AuCl, (p-cymene)RuCl2, (p-cymene)OsCl2, (Cp*)RhCl2, or Au-thioglucose) are the two general features of these complexes. All of the bimetallic compounds have been evaluated for their antiproliferative properties in vitro in human cancer cell lines. Only the complexes containing an Au(I) fragment exhibit antiproliferative activity in the range of cisplatin or higher. The photophysical and electrochemical properties of the bimetallic species have been investigated, and fluorescence microscopy experiments have been performed successfully. The most promising bimetallic cytotoxic complexes (i.e., with the Au-thioglucose scaffold) have shown to be easily taken up by cancer cells at 37 °C in the cytoplasm or in specific organelles. Interestingly, experiments repeated at 4 °C showed no uptake of the bimetallic species inside cells, which confirms involvement of active transport processes. To evaluate the role of glucose transporters in the cell uptake of the gold complexes, inhibition of the GluT-1 (glucose transporter isoform with high level of expression in cancer cells) was achieved, showing only scarce influence on the compounds’ uptake. Finally, the observed absence of interactions with nucleic acid model structures suggests that the gold compounds may have different intracellular targets with respect to cisplatin.


  • New heteronuclear gold(I)–platinum(II) complexes with cytotoxic properties: Are two metals better than one?

    by Margot Wenzel, Emilia Bigaeva, Philippe Richard, Pierre Le Gendre, Michel Picquet, Angela Casini, Ewen Bodio


  • Multinuclear Cytotoxic Metallodrugs: Physicochemical Characterization and Biological Properties of Novel Heteronuclear Gold–Titanium Complexes

    by Margot Wenzel, Benoît Bertrand, Marie-Joëlle Eymin, Virginie Comte, Jennifer A. Harvey, Philippe Richard, Michael Groessl, Olivier Zava, Hedi Amrouche, Pierre D. Harvey, et al.

    An unprecedented series of titanocene–gold bi- and trimetallic complexes of the general formula [[(η5-C5H5)(μ-η5:κ1-C5H4(CH2)nPPh2)TiCl2]mAuClx]q+ (n = 0, 2, or 4; m = 1, x = 1, q = 0 or m = 2, x = 0, q = 1) have been prepared and characterized spectroscopically. The luminescence spectroscopy and photophysics of one of the compounds, [[(η5-C5H5)(μ-η5:κ1-C5H4PPh2)TiCl2]2Au]PF6, have been investigated in 2MeTHF solution and in the solid state at 77 and 298 K. Evidence for interfragment interactions based on the comparison of electronic band positions and emission lifetimes, namely, triplet energy transfer (ET) from the Au- to the Ti-containing chromophores, is provided. The cytotoxicity of the complexes was evaluated on A2780 ovarian cancer cells and on their cisplatin-resistant cell line A2780cisR; the compounds showed activity in the low micromolar range that was markedly more active than the corresponding titanocene–phosphine precursors [(η5-C5H5)(η5-C5H4(CH2)nPPh2)TiCl2], cisplatin, and, for some of them, the gold analogue [(PPh3)AuCl]. In an attempt to draw preliminary structure–activity relationships, cell uptake measurements and interaction studies with plasmid DNA and the model protein ubiquitin (Ub) have been undertaken on some of the compounds.


  • Development of Bimetallic Titanocene−Ruthenium−Arene Complexes As Anticancer Agents: Relationships between Structural and Biological Properties

    by Frédéric Pelletier, Virginie Comte, Alexandre Massard, Margot Wenzel, Stéphanie Toulot, Philippe Richard, Michel Picquet, Pierre Le Gendre, Olivier Zava, Fabio Edafe, et al.

    A series of bimetallic titanium−ruthenium complexes of general formula [(η5-C5H5)(μ-η5:κ1-C5H4(CR2)nPR′R′′)TiCl2](η6-p-cymene)RuCl2 (n = 0, 1, 2 or 4; R = H or Me; R′ = H, Ph, or Cy; R′′ = Ph or Cy) have been synthesized, including two novel compounds as well as two cationic derivatives of formula [(η5-C5H5)(μ-η5:κ1-C5H4(CH2)nPPh2)TiCl2] [(η6-p-cymene)RuCl](BF4) (n = 0 or 2). The solid state structure of two of these compounds was also established by X-ray crystallography. The complexes showed a cytotoxic effect on human ovarian cancer cells and were markedly more active than their Ti or Ru monometallic analogues titanocene dichloride and RAPTA-C, respectively. Studies of cathepsin B inhibition, an enzyme involved in cancer progression, showed that enzyme inhibition by the bimetallic complexes is influenced by the length of the alkyl chain in between the metal centers. Complementary ESI-MS studies provided evidence for binding of a Ru(II) fragment to proteins.